FibroGen, Inc. (FGEN)

NASDAQ: FGEN · IEX Real-Time Price · USD
2.350
-0.230 (-8.91%)
At close: Mar 28, 2024, 4:00 PM
2.388
+0.038 (1.62%)
After-hours: Mar 28, 2024, 7:49 PM EDT

Total Valuation

FibroGen has a market cap or net worth of $236.06 million. The enterprise value is $204.44 million.

Market Cap 236.06M
Enterprise Value 204.44M

Important Dates

The next estimated earnings date is Monday, May 6, 2024, after market close.

Earnings Date May 6, 2024
Ex-Dividend Date n/a

Share Statistics

FibroGen has 98.77 million shares outstanding. The number of shares has increased by 3.98% in one year.

Shares Outstanding 98.77M
Shares Change (YoY) +3.98%
Shares Change (QoQ) +0.27%
Owned by Insiders (%) 6.37%
Owned by Institutions (%) 71.45%
Float 82.99M

Valuation Ratios

PE Ratio n/a
Forward PE 61.35
PS Ratio 1.60
Forward PS 1.47
PB Ratio n/a
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 1.38
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.52

Current Ratio 1.52
Quick Ratio 1.14
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -17.30

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -58.70%
Return on Capital (ROIC) n/a
Revenue Per Employee $304,016
Profits Per Employee -$584,840
Employee Count 486
Asset Turnover 0.31
Inventory Turnover 0.46

Taxes

In the past 12 months, FibroGen has paid $3,000 in taxes.

Income Tax 3,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -87.51% in the last 52 weeks. The beta is 0.66, so FibroGen's price volatility has been lower than the market average.

Beta (1Y) 0.66
52-Week Price Change -87.51%
50-Day Moving Average 1.93
200-Day Moving Average 1.95
Relative Strength Index (RSI) 56.05
Average Volume (30 Days) 2,627,211

Short Selling Information

The latest short interest is 5.53 million, so 5.60% of the outstanding shares have been sold short.

Short Interest 5.53M
Short Previous Month 6.52M
Short % of Shares Out 5.60%
Short % of Float 6.66%
Short Ratio (days to cover) 3.12

Income Statement

In the last 12 months, FibroGen had revenue of $147.75 million and -$284.23 million in losses. Loss per share was -$2.92.

Revenue 147.75M
Gross Profit 128.90M
Operating Income -281.82M
Pretax Income -284.23M
Net Income -284.23M
EBITDA -258.77M
EBIT -268.70M
Loss Per Share -$2.92
Full Income Statement

Balance Sheet

The company has $235.59 million in cash and $203.96 million in debt, giving a net cash position of $31.63 million or $0.32 per share.

Cash & Cash Equivalents 235.59M
Total Debt 203.96M
Net Cash 31.63M
Net Cash Per Share $0.32
Equity / Book Value -204.17M
Book Value Per Share -2.07
Working Capital 113.89M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$315.02 million and capital expenditures -$2.52 million, giving a free cash flow of -$317.54 million.

Operating Cash Flow -315.02M
Capital Expenditures -2.52M
Free Cash Flow -317.54M
FCF Per Share -$3.26
Full Cash Flow Statement

Margins

Gross margin is 87.24%, with operating and profit margins of -190.74% and -192.37%.

Gross Margin 87.24%
Operating Margin -190.74%
Pretax Margin -192.37%
Profit Margin -192.37%
EBITDA Margin -175.14%
EBIT Margin -181.86%
FCF Margin -214.91%

Dividends & Yields

FibroGen does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -3.98%
Shareholder Yield -3.98%
Earnings Yield -120.41%
FCF Yield -134.51%

Analyst Forecast

The average price target for FibroGen is $5.00, which is 112.77% higher than the current price. The consensus rating is "Sell".

Price Target $5.00
Price Target Difference 112.77%
Analyst Consensus Sell
Analyst Count 5
Revenue Growth Forecast (5Y) 11.71%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

FibroGen has an Altman Z-Score of -7.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -7.27
Piotroski F-Score 2